Mombelli L, Inversini G, Conte L, Favarò L, Cinquepalmi N, Grasso A
Radiol Med. 1981 Apr;67(4):235-42.
Measurements of the doses were carried out on phantoms in order to determine the dose in the marrow and gonads of patients undergoing radio-therapeutic treatment with telecobalt therapy with fixed fields. On average, the dose in the marrow for each treatment resulted to be 2.35 Gy in the male and 5.8 Gy in the female whereas the dose in the gonads for each treatment was on average 0.41 Gy in the male and 0.029 Gy with the exclusion of castrating doses in the female. If one considers the number of patients treated in 1975 with telecobalt therapy with fields (269 men and 309 women) the contribution to the leukaemia dose and to the genetically significant dose can be estimated in approximate terms for the year 1975 in the province of Varese: 0.48 mSv/year and 2.5.10-3 mSv/year respectively. Taking into account the risk factors indicated in publication 26 of the ICRP it can be deduced that in the group of patients treated the expected increase in the number of cases of leukaemia and genetic effects will be 5 and 0.5 respectively.
为了确定接受固定野远距离钴治疗的放射治疗患者骨髓和性腺中的剂量，在体模上进行了剂量测量。平均而言，每次治疗男性骨髓中的剂量为2.35 Gy，女性为5.8 Gy，而每次治疗性腺中的剂量男性平均为0.41 Gy，女性排除去势剂量后平均为0.029 Gy。如果考虑1975年接受固定野远距离钴治疗的患者数量（269名男性和309名女性），则可以大致估算出1975年瓦雷泽省对白血病剂量和遗传显著剂量的贡献：分别为0.48 mSv/年和2.5×10⁻³ mSv/年。考虑到国际放射防护委员会第26号出版物中指出的风险因素，可以推断出在接受治疗的患者组中，白血病病例数和遗传效应的预期增加分别为5例和0.5例。
